ClinicalTrials.gov record
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

ClinicalTrials.gov ID: NCT02576275

Public ClinicalTrials.gov record NCT02576275. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 12:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination With Rituximab and Bendamustine vs Placebo Administered in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma

Study identification

NCT ID
NCT02576275
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 3
Lead sponsor
SecuraBio
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

  • Bendamustine Drug
  • Duvelisib Drug
  • Placebo Drug
  • Rituximab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2015
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016
Last update posted
Mar 16, 2021

2015 – 2016

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Not listed Plainville Connecticut 06062
Not listed Plantation Florida 33322
Not listed Thomasville Georgia 31792
Not listed East Setauket New York 11733-3456
Not listed Cookeville Tennessee 38501
Not listed Knoxville Tennessee 37909
Not listed Spokane Washington 99208

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02576275, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 16, 2021 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02576275 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →